Structured evidence table for Chromium Glucose Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Glucose Randomized Trial | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Glucose Randomized Trial | While women in developing countries may display lean PCOS phenotypes with severe reproductive dysfunction, women in industrialized countries frequently present with obesity-associated insulin resistance and metabolic syndrome (). | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
| Chromium Glucose Randomized Trial | Given the growing body of evidence linking micronutrient status to PCOS pathophysiology, there is a need to consolidate existing mechanistic and clinical evidence. | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
| Chromium Glucose Randomized Trial | The following sections examine each micronutrient’s molecular targets and clinical relevance, integrating evidence from observational studies and randomized trials with mechanistic data from cellular and animal models to clarify their potential to modulate key pathways underlying insulin resistance, hyperandrogenism, oxidative stress, and inflammation in PCOS. | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
| Chromium Glucose Randomized Trial | 1 2 Polycystic Ovary Syndrome (PCOS) stands as one of the most prevalent endocrine–metabolic conditions affecting women during their reproductive years at a rate of 21% worldwide and varies from 7% to 20% in Indian women based on different diagnostic standards. | 3 | Natarajan Madhumitha (2026) | Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential |
Source documents